The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors

Seminars in Oncology

Volumn 30, Issue 1 SUPPL. 1, 2003, Pages 3-11

  Ritter, Christoph A ^a   Arteaga, Carlos L ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PACLITAXEL; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOWN REGULATION; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENDOCYTOSIS; ENZYME ACTIVATION; GASTROINTESTINAL TOXICITY; HUMAN; LIGAND BINDING; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR;

EID: 0037296357     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50027     Document Type: Article

References (69)

1. Zwick E, Bange J, Ullrich A: Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8:161-173, 2001
2. Prenzel N, Fischer OM, Streit S, et al: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31, 2001
3. Agus DB, Bunn PA Jr, Franklin W, et al: HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 27:53-63, 2000 (suppl 11)
4. Sawyers CL: Cancer treatment in the ST1571 era: What will change? J Clin Oncol 19:13S-16S, 2001 (suppl)
5. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145, 2000
6. Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60:15-23, 2000 (suppl 1)
7. Olayioye MA, Neve RM, Lane HA, et al: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000
8. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
9. Yarden Y: The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:3-8, 2001 (suppl 4)
10. Pinkas-Kramarski R, Soussan L, Waterman H, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467, 1996
11. Graus-Porta D, Beerli RR, Hynes NE: Single-chain antibody mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 15:1182-1191, 1995
12. Fedi P, Pierce JH, Di Fiore PP, et al: Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or OTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 14:492-500, 1994
13. Levkowitz O, Waterman H, Zamir E, et al: c-Cbl/Sli-I regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Der 12:3663-3674, 1998
14. Baulida J, Kraus MH, Alimandi M, et al: All ErhB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271:5251-5257, 1996
15. Moasser MM, Basso A, Averbuch SD, et al: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188, 2001
16. Moulder SL, Yakes FM, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001
17. Wells A: EGF receptor. Int J Biochem Cell Biol 31:637-643, 1999
18. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
19. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
20. Fontanini O, De Laurentiis M, Vignati S, et al: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangingenesis in complately resected stage I-IIIA non-small-call lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241-249, 1998
21. Grandis JR, Melhem MF, Gooding WE, et al: Levels of TOF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998
22. Downward J, Yarden Y, Mayes E, et al: Close similarity of epidermal growth factor receptor and v-evb-B oncogene protein sequences. Nature 307:521-527, 1984
23. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
24. Bundred NJ, Chan K, Anderson NO: Studies of epidermal growth factor receptor inhibition in breast cancer. Endocr Relat Cancer 8:183-189, 2001
25. Kelloff OJ, Fay JR, Steele VE, et al: Epidermal growth factor receptor tyrosine kinase, inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 5:657-666, 1996
26. Kurie JM, Shin HJG, Lee JS, et al: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2:1787-1793, 1996
27. Sauter O, Maeda T, Waldman FM, et al: Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 148:1047-1053, 1996
28. Wong AJ, Ruppert JM, Bigner SH, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992
29. Moscatello DK, Holgado-Madruga M, Godwin AK, et al: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539, 1995
30. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999
31. Baselga J, Mendelsohn J: Type I receptor tyrosine kirinses as targets for therapy in breast cancer. J Mammary Gland Biol Neoplasia 2:165-174, 1997
32. Wu X, Fan Z, Masui H, et al: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897-1905, 1995
33. Goldstein HI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318, 1995
34. Fan Z, Masui H, Altas I, et al: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322-4328, 1993
35. Divgi CR, Welt S, Kris M, et al: Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83:97-104, 1991
36. Tateishi M, Ishida T, Kohdono S, et al: Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 3:109-113, 1994
37. Xia W, Lau Y-K, Zhang H-Z, et al: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5:4164-4174, 1999
38. Tateishi M, Ishida T, Mitsudomi T, et al: Immunohistochemical evidence of autoctine growth factors in adenocarcinoma of the human lung. Cancer Res 50:7077-7080, 1990
39. Veale D, Kerr N, Gibson GJ, et al: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68:162-165, 1993
40. Maurizi M, Almadori G, Ferrandina G, et al: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74:1253-1257, 1996
41. Yonemura Y, Takamura H, Ninomiya I, et al: Interrelationship between transforming growth factor-α and epidermal growth factor receptor in advanced gastric cancer. Oncology 49:157-161, 1992
42. Yamanaka Y, Friess H, Kobrin MS, et al: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565-569, 1993
43. Uegaki K, Nio Y, Inoue Y, et al: Clinicopathological significance of epidermal growth factor and its receptor in hmnan pancreatic cancer. Anticancer Res 17:3841-3847, 1997
44. Messa C, Russo F, Caruso MG, et al: EGF, TGF-α, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 37: 285-289, 1998
45. Mayer A, Takimoto M, Fritz E, et al: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454-2460, 1993
46. Klijn JG, Berns PMJJ, Schmitz PI, et al: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 13:3-17, 1992
47. Klijn JGM, Look MP, Portengen H, et al: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study. Breast Cancer Res Treat 29:73-83, 1994
48. Sharma AK, Horgan K, Douglas-Jones A, et al: Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 69:1032-1037, 1994
49. Bartlett JMS, Langdon SP, Simpson BJB, et al: The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 73:301-306, 1996
50. Niikura H, Sasano H, Sato S, et al: Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol 16:60-68, 1997
51. Ekstrand AJ, James CD, Cavenee WK, et al: Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164-2172, 1991
52. Harris AL, Nicholson S, Sainsbury JRC, et al: Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34:123-131, 1989
53. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 55:2379-2385, 1993
54. Yoshida K, Hosoya Y, Sumi S, et al: Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: A comparison of immunohistochemical method versus ligand binding assay. Oncology 54:220-225, 1997
55. Türkeri LN, Erton ML, Çevik I, et al: Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 51:645-649, 1998
56. Chow N-H, Liu H-S, Yang H-B, et al: Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma: An immunnhistochemical study. Virchows Arch 430:461-466, 1997
57. Neal DE, Sharples L, Smith K, et al: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65:1619-1625, 1990
58. Al-Obeidi FA, Lam KS: Development of inhibitors for protein tyrosine kinases. Oncogene 19:5690-5701, 2000
59. Fry DW: Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 15:3-16, 2000
60. Arteaga CL: The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19:32s-40s, 2001 (suppl)
61. Baselga J, Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs 60:33-40, 2000 (suppl 1)
62. Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002
63. Moyer JD, Barbacci EG, lwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitur of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848, 1997
64. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase 1 and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
65. Siromak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
66. Rodeck U, Herlyn M, Herlyn D, et al: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects. Cancer Res 47:3692-3696, 1987
67. Sampson JH, Crotty LE, Lee S, et al: Unarmed, tumor-specific monodonal antibody effectively treats brain tumors. Proc Nad Acad Sci U S A 97:7503-7508, 2000
68. Perez-Soler R, Donato NJ, Shin DM, et al: Tumor epidermal growth factor receptor studies in patients with nonsmall-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 12:730-739, 1994
69. Anderson NG, Ahmed T, Chart K, et al: ZD1839 (lressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94:774-782, 2001